Library / Regulatory / State map / Delaware
DE · State regulatory reference

Delaware.

Moderate

Delaware's telehealth practice-of-medicine and prescribing rules are codified in Title 24, Chapter 60 (24 Del. C. §§ 6001–6005; the former § 1769D was repealed and recodified into Chapter 60 in 2021). Section 6003 requires a provider-patient relationship and bars prescribing solely from an internet questionnaire, internet consult, or telephone consult; § 6004 allows that relationship to be established via synchronous audio-video. Compounding under the Board of Pharmacy's 24 DE Admin. Code 2500 requires FDCA 503A, FDA compounding, and USP <795>/<797> compliance, with no Delaware-specific GLP-1/semaglutide restriction. No documented Delaware board enforcement against peptide/GLP-1 compounding was located.

Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
An initial evaluation and prescribing may occur via synchronous audio-video once a valid provider-patient relationship is established (24 Del. C. § 6004); prescriptions issued solely from an internet questionnaire, internet consult, or telephone consult without that relationship are prohibited (§ 6003).
Compounding
24 DE Admin. Code 2500 (Board of Pharmacy) requires 503A/FDA compliance and USP <795>/<797> beyond-use dating but adds no drug-specific limits; no GLP-1, semaglutide, or tirzepatide restriction appears in the rule.
Sources
  1. 01 24 Del. C. Chapter 60 — Telehealth and Telemedicine (§§ 6001–6005), official Delaware Code ↗
  2. 02 24 Del. Admin. Code § 2500-5.0 (Board of Pharmacy — Dispensing/Compounding; 503A + USP 795/797) — via Cornell LII ↗
← Back to state map